sk&f 86002 has been researched along with Central Nervous System Neoplasms in 1 studies
6-(4-fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole: inhibits p38 MAP kinase
Central Nervous System Neoplasms: Benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Based on promising preclinical results, we conducted a pediatric phase I study to estimate the maximum tolerated dose, describe dose-limiting toxicities (DLT) and characterize the pharmacokinetic profile of PTC299 in children with recurrent CNS tumors." | 2.80 | Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study. ( Banerjee, A; Boyett, JM; Fisher, M; Fouladi, M; Goldman, S; Kun, L; Lulla, R; Onar-Thomas, A; Packer, RJ; Pollack, I; Rood, BR; Smith, C; Stewart, CF; Turner, DC; Wu, S; Young-Pouissant, T, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Packer, RJ | 1 |
| Rood, BR | 1 |
| Turner, DC | 1 |
| Stewart, CF | 1 |
| Fisher, M | 1 |
| Smith, C | 1 |
| Young-Pouissant, T | 1 |
| Goldman, S | 1 |
| Lulla, R | 1 |
| Banerjee, A | 1 |
| Pollack, I | 1 |
| Kun, L | 1 |
| Onar-Thomas, A | 1 |
| Wu, S | 1 |
| Boyett, JM | 1 |
| Fouladi, M | 1 |
1 trial available for sk&f 86002 and Central Nervous System Neoplasms
| Article | Year |
|---|---|
Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study.
Topics: Adolescent; Antineoplastic Agents; Central Nervous System Neoplasms; Child; Child, Preschool; Female | 2015 |